Nursing care
Chemotherapy Agents: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 6 min read · Updated September 2026
Short answer
Chemotherapy agents work by disrupting rapidly dividing cells, which is why they target tumours and also damage bone marrow, mucosa, and hair follicles. The nadir, when blood counts bottom out, typically occurs 7 to 10 days after administration, and that window is when neutropenic precautions and infection monitoring matter most.
What it does and why it is prescribed
Chemotherapy agents interfere with cell division, either by damaging DNA directly, blocking the enzymes cells need to replicate, or disrupting the mitotic spindle. Cancer cells divide faster than most normal cells, so they are hit hardest, but any tissue with a fast turnover, bone marrow, gastrointestinal lining, hair follicles, is affected too. That shared mechanism is why the toxicity profile looks similar across drug classes even though the specific agents differ widely.
Regimens are usually combined, pairing agents that act at different points in the cell cycle to increase kill rate and reduce the chance of resistant cells surviving. The choice of agent, dose, and schedule depends on cancer type, stage, and the patient's organ function, particularly renal and hepatic function, since many agents are cleared through one or both.
Nursing considerations before giving it
Confirm current lab values before administration: complete blood count with differential, renal function, and hepatic function, since dosing is frequently adjusted or held based on these results. Verify the order against the patient's body surface area calculation and confirm two-nurse independent verification per institutional policy, since chemotherapy dosing errors carry high harm potential.
Confirm venous access is appropriate for the agent. Vesicant drugs, which cause tissue damage if they extravasate, require a central line or a nurse credentialed to administer peripherally with strict monitoring; irritants and non-vesicants have different access requirements. Check the patient's antiemetic premedication has been given on schedule, since several agents are highly emetogenic and pretreatment significantly improves tolerance.
Confirm informed consent is documented and that the patient understands the treatment plan, since chemotherapy administration typically requires this as a discrete step separate from general procedural consent.
What to monitor
Monitor the complete blood count on a schedule tied to the nadir, the point at which white cells, particularly neutrophils, and often platelets and red cells, reach their lowest point. For most conventional agents this falls at 7 to 10 days post-treatment, though the exact timing varies by drug and regimen. Counts should be checked around this window so falling values are caught before infection or bleeding risk peaks.
During infusion, monitor for infusion reactions, extravasation at the site for vesicant agents, and vital sign changes. After administration, monitor oral mucosa daily for mucositis, monitor bowel pattern for both diarrhoea and constipation depending on the agent, and monitor weight and intake for cumulative nutritional impact over a treatment course.
Monitor site-specific toxicities relevant to the specific agent given, such as cardiac function with anthracyclines or peripheral sensation with vinca alkaloids and platinum agents, since these are cumulative and dose-limiting rather than acute.
Side effects versus adverse effects
Side effects are expected, predictable consequences of the drug's mechanism that occur at normal doses, things like nausea, alopecia, fatigue, and the myelosuppression that produces the nadir. These are anticipated, managed proactively with premedication and supportive care, and do not usually require stopping treatment.
Adverse effects are unintended, often more serious reactions that may or may not be dose-related, such as anaphylaxis, severe extravasation injury, cardiotoxicity, or organ failure. These are not simply an intensified version of an expected side effect; they represent harm the treatment plan did not anticipate and typically require the dose to be held, reduced, or the regimen changed.
The distinction matters clinically because the response differs: a side effect gets managed with supportive care within the existing plan, an adverse effect gets reported, documented, and escalated to reassess whether treatment should continue.
What to hold for and when to call
Hold the dose and notify the prescriber for an absolute neutrophil count below the threshold set in the regimen protocol, since administering into significant neutropenia raises infection risk substantially. Hold for a fever at or above 38°C (100.4°F) in a neutropenic patient, which is treated as a medical emergency requiring prompt evaluation and often empiric antibiotics, not observation.
Hold for signs of extravasation at a vesicant infusion site, stopping the infusion immediately and following the institution's extravasation protocol rather than continuing to assess. Hold for significant thrombocytopenia with active bleeding, and for signs of an infusion or hypersensitivity reaction such as dyspnoea, hypotension, or facial swelling, which requires stopping the infusion and initiating the reaction protocol immediately.
Call promptly for new-onset chest pain or dyspnoea in a patient on a cardiotoxic agent, and for any unexplained neurological change in a patient on a neurotoxic agent, since these can signal cumulative organ damage that changes the treatment plan.
Patient teaching
Teach the patient to recognise fever as a reason to seek care immediately rather than waiting it out, and to understand the nadir window, roughly 7 to 10 days after treatment, as the period of highest infection risk, when they should avoid crowds, sick contacts, and raw or undercooked food.
Teach good oral hygiene with a soft toothbrush to reduce mucositis risk, and to report mouth sores early since they affect nutrition and can become a source of infection during neutropenia. Teach the patient to report unusual bruising or bleeding, which can signal thrombocytopenia, and to avoid nonsteroidal anti-inflammatory drugs and aspirin unless specifically approved, since these increase bleeding risk on top of treatment-related thrombocytopenia.
Teach realistic expectations around hair loss and fatigue as expected effects, while being clear about the specific symptoms, fever, bleeding, breathlessness, that are not routine and need same-day contact with the care team rather than being managed at home.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
When exactly does the chemotherapy nadir occur?
The nadir, the lowest point of blood cell counts, typically occurs 7 to 10 days after chemotherapy administration for most conventional agents, though timing varies by drug and regimen. Counts usually begin recovering within a further 1 to 2 weeks, and labs are scheduled around this window to catch the drop early.
What precautions should a patient follow during the nadir?
Neutropenic precautions apply: avoiding crowds and known sick contacts, practising strict hand hygiene, avoiding raw or undercooked food, and monitoring temperature closely. Any fever at or above 38°C (100.4°F) during this window should prompt immediate medical evaluation rather than waiting.
What is the difference between a vesicant and an irritant chemotherapy drug?
A vesicant causes tissue necrosis if it extravasates outside the vein, so it requires central access or highly monitored peripheral administration and an immediate stop-and-protocol response if extravasation occurs. An irritant can cause discomfort or inflammation at the site but does not typically cause tissue death, so the response to a leak is less urgent, though still requires monitoring.
Why do chemotherapy agents cause hair loss and mouth sores?
Both hair follicles and the lining of the mouth are made of rapidly dividing cells, the same property that makes tumour cells vulnerable to chemotherapy. Because the drugs cannot fully distinguish fast-dividing healthy cells from cancer cells, these normal tissues are affected as a predictable, expected side effect rather than a sign the drug is malfunctioning.
Is nausea from chemotherapy a side effect or an adverse effect?
Nausea is a side effect: an expected, predictable result of the drug's mechanism that is managed proactively with antiemetic premedication. An adverse effect would be something unanticipated and more serious, like an anaphylactic reaction, which requires stopping the infusion and escalating care rather than managing with routine supportive measures.
More on pharmacology
Guides on this